{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T21:52:21Z","timestamp":1769723541550,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.humpath.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T16:21:45Z","timestamp":1718986905000},"page":"86-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Application and pitfalls of immunophenotyping in challenging plasma cell neoplasms: A case series"],"prefix":"10.1016","volume":"150","author":[{"given":"Elena","family":"Frye Naharro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia L.","family":"Yohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Linden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.06.012_bib1","first-page":"221","article-title":"VS38 Identifies myeloma cells with dim CD38 expression and plasma cells following daratumumab therapy, which interferes with CD38 detection for 4 to 6 months","volume":"153","author":"Courville","year":"2020","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib2","series-title":"WHO Classification of tumors of hematopoietic and lymphoid tissues","first-page":"241","author":"McKenna","year":"2017"},{"key":"10.1016\/j.humpath.2024.06.012_bib3","article-title":"Plasma cell myeloma\/multiple myeloma. WHO classification of tumours editorial board","volume":"11","author":"Kumar","year":"2024","journal-title":"Haematolymphoid tumours [Internet] (International Agency for Research on Cancer, Lyon (France), ed. 5th edition"},{"key":"10.1016\/j.humpath.2024.06.012_bib4","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","article-title":"Phenotypic difference of normal plasma cells from mature myeloma cells","volume":"81","author":"Harada","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.06.012_bib5","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib6","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.06.012_bib7","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1373\/jalm.2016.020883","article-title":"Standardization of minimal residual disease testing in multiple myeloma","volume":"2","author":"Baughn","year":"2017","journal-title":"J Appl Lab Med"},{"key":"10.1016\/j.humpath.2024.06.012_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.humpath.2024.06.012_bib10","series-title":"SpringerLink, plasma cell neoplasms : a morphologic, Cytogenetic and immunophenotypic approach","author":"Linden","year":"2016"},{"key":"10.1016\/j.humpath.2024.06.012_bib11","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.06.012_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2024.06.012_bib13","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2024.06.012_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41408-021-00529-w","article-title":"Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study","volume":"11","author":"Staron","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.humpath.2024.06.012_bib15","article-title":"Immunoglobulin-related amyloidosis (AL amyloidosis). WHO classification of tumours editorial board. Haematolymphoid tumours [internet]","volume":"11","author":"Wechalekar","year":"2024","journal-title":"International Agency for Research on Cancer, Lyon (France)"},{"key":"10.1016\/j.humpath.2024.06.012_bib16","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2024.06.012_bib17","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4161\/mabs.21614","article-title":"Characterization of antibody variants during process development: the tale of incomplete processing of N-terminal secretion peptide","volume":"4","author":"Ambrogelly","year":"2012","journal-title":"mAbs"},{"key":"10.1016\/j.humpath.2024.06.012_bib18","first-page":"8536","article-title":"Biphenotypic plasma cell myeloma: two cases of plasma cell neoplasm with a coexpression of kappa and lambda light chains","volume":"8","author":"Jiwani","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib19","first-page":"4718","article-title":"Plasma cell myeloma with dual expression of kappa and lambda light chains","volume":"11","author":"Jiang","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.humpath.2024.06.012_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3324\/haematol.2010.030882","article-title":"Emergence of oligoclonal bands in patients with multiple myeloma in complete remission after induction chemotherapy: association with the use of novel agents","volume":"96","author":"Fern\u00e1ndez de Larrea","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.humpath.2024.06.012_bib22","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","article-title":"Advances in therapeutic fc engineering - modulation of IgG-associated effector functions and serum half-life","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.humpath.2024.06.012_bib23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/MPH.0000000000000907","article-title":"Plasma cell myeloma in children and young adults: a report of 4 cases from a single institution and a review of the literature","volume":"39","author":"Yohe","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.humpath.2024.06.012_bib24","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.morpho.2015.02.001","article-title":"Plasma cell morphology in multiple myeloma and related disorders","volume":"99","author":"Ribourtout","year":"2015","journal-title":"Morphologie"},{"key":"10.1016\/j.humpath.2024.06.012_bib25","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1309\/LMG2FH0J2YINEUMM","article-title":"Crystallizing immunoglobulin presenting as polychromatic crystalline keratopathy: an unusual clinical presentation of monoclonal gammopathy of undetermined significance (MGUS)","volume":"44","author":"Conway","year":"2013","journal-title":"Lab Med"},{"key":"10.1016\/j.humpath.2024.06.012_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/dc.23168","article-title":"Atypical blast morphology of primary plasma cell leukemia with renal involvement and plasmablasts in urine","volume":"43","author":"Pavlovic","year":"2015","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.humpath.2024.06.012_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities-evolution in diagnosis and classification","volume":"482","author":"Fend","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2024.06.012_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.humpath.2024.06.012_bib29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724001205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T16:34:04Z","timestamp":1722011644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724001205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":29,"alternative-id":["S0046817724001205"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.06.012","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application and pitfalls of immunophenotyping in challenging plasma cell neoplasms: A case series","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}